Optimi Health (TSE:OPTI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Optimi Health Corp. has received a Drug Establishment Licence from Health Canada, enabling the company to manufacture and sell GMP-compliant MDMA and psilocybin capsules for patients with PTSD and Treatment-Resistant Depression in Australia and potentially worldwide. This significant achievement allows Optimi to begin the process of registering the drugs with the U.S. FDA and to supply initial doses to fulfill prescriptions through Mind Medicine Australia. The licence positions Optimi as a key player in the burgeoning global psychedelics market, with a fully operational infrastructure to commercialize their pharmaceutical-grade products.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.